Current position

Ray Dalio’s Gilead Sciences Inc (GILD) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2009Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares1.01MHighest verified quarter-end share count
Quarters reported46Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Gilead Sciences Inc in Q2 2009. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 290.88K shares. The latest verified filing showed: Bought 60.9% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 60.9% more+110.14K shares · 290.88K shares reported after the change
Filing context

Quarter-end price $126.34 · Estimated holding basis $105.17

Q1 2026
Sold 38.2% of the position−111.67K shares · 180.74K shares remained
Filing context

Quarter-end price $139.37 · Estimated holding basis $92.27

Q4 2025
Sold 24.1% of the position−92.96K shares · 292.41K shares remained
Filing context

Quarter-end price $122.74 · Estimated holding basis $92.27

Q3 2025
Sold 42.2% of the position−280.94K shares · 385.36K shares remained
Filing context

Quarter-end price $111.00 · Estimated holding basis $92.27

Q2 2025
Bought 32.5% more+163.35K shares · 666.30K shares reported after the change
Filing context

Quarter-end price $110.87 · Estimated holding basis $92.27

Q1 2025
Bought 9.1% more+42.02K shares · 502.95K shares reported after the change
Filing context

Quarter-end price $112.05 · Estimated holding basis $86.23

Portfolio importance

How important is Gilead Sciences Inc in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.2%Q2 2026
Current rank#111of 997 reported positions
Peak portfolio weight0.4%Q4 2014
Best historical rank#5Q4 2014
At peak importanceQ4 2014
GILD
0.4%
Largest holding
37.1%
Cross-investor discovery

Who else owns Gilead Sciences Inc?

Also reported by 1 other tracked investor in their latest verified filings.

Joel GreenblattGotham Asset Management
GILD0.1% of reported portfolio
Explore Gilead Sciences Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$146.412026-09-14

Market context only; not an investor transaction price.

Latest filing quarter-end price$126.34Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$105.17Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.